A Phase 2, open-label, placebo-controlled trial of topical itraconazole 0.7% gel applied for 1–3 months in BCC treatment did not yield reduction of GLI1 mRNA expression or tumor size [126]. This evidence concerns the gene GLI1 and neoplasm.